1. Inicio
  2. Publicaciones
  3. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martínez-López J
  • Paiva B
  • López-Anglada L
  • Mateos MV
  • Cedena T
  • Vidríales MB
  • Sáez-Gómez MA
  • Contreras T
  • Oriol A
  • Rapado I
  • Teruel AI
  • Blanchard MJ
  • Bengoechea E
  • Palomera L
  • de Arriba F
  • Cueto-Felgueroso C
  • Orfao A
  • Bladé J
  • San Miguel JF
  • Lahuerta JJ
  • Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseas

Grupos

Abstract

Stringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised.

Datos de la publicación

ISSN/ISSNe:
0006-4971, 1528-0020

BLOOD  ELSEVIER

Tipo:
Article
Páginas:
858-862
PubMed:
26089396
Factor de Impacto:
6,353 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 54

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; FREE LIGHT-CHAIN; SURVIVAL; IMMUNOFIXATION; INDUCTION; THERAPY

Campos de Estudio

Compartir